Effects of BmkTXK Beta on Electrophysiological Properties of Rabbit Atrial Myocytes.
D Hu,Cx Huang,H Jiang,Gs Li,Zj Cao,Wx Li,Sm Wang
2003-01-01
Abstract:Objective To investigate the effects of BmkTXK(beta), a newly purified 'long chain' peptide inhibitor of K+ channels from the Chinese scorpion Buthus martensi Karsch (BmK), on the electrophysiological properties of isolated rabbit atrial myocytes.Methods The standard whole-cell patch-clamp technique was used to study the effects of multiple concentrations of BmkTXK(beta) on potassium currents and action potentials.Results BmkTXK(beta) produced concentration-dependent prolongation of action potential duration at 20%, 50%, and 90% repolarization (APD(20,50,90)) without any use-dependence. Meanwhile, it had no significant effect on RMP, APA, or V-max (n=9). At a dose of 1 mumol/L, BmkTXK(beta) decreased I-to by 41.4% (n=10, P<0.01) at a membrane potential of +50 mV [from (13.63&PLUSMN;0.87) pA/pF to (7.98&PLUSMN;0.78) pA/pF]. I-to was reduced significantly with an IC50 value of 1.82 μmol/L (95% confidence interval: 1.47-2.17 μmol/L), in a clear concentration-dependent manner. BmkTXK(β) blocked I-Ks and I-Ks,I-tail with an IC50 of 20.15 μmol/L and a 95% confidence interval of 16.93-23.37 μmol/L. At a concentration of 10 μmol/L, BmkTXK(β) blocked both I-Ks (mean reduction 37.3%&PLUSMN;4.2%, P<0.01, n=7) and I-Ks,I-tail (mean reduction 35.8%+/-4.1%, P<0.01, n=7). At 0 mV, 10 μmol/L BmkTXK(β) inhibited both I-Kr (mean reduction 40.5%&PLUSMN;2.6%, P<0.01, n=6) and I-Kr,I-tail (mean reduction 42.3%+/-2.9%, P<0.01, n=6). Blocking of I-Kr by BmkTXK(β) occurred in a concentration-dependent manner, with an IC50 of 17.21 μmol/L (95% confidence interval: 14.76-19.66 μmol/L). An absence of effects on I-K1 was observed for BmkTXK(β), with no change in reversal-potential (n=6, P>0.05).Conclusions BmkTXK(beta) exerts direct blocking effects on several potassium channels involved in cardiac repolarization, and has a strong effect on prolonging the repolarization of rabbit cardiomyocytes without reverse frequency dependence. This finding suggests that BmkTXK(beta) could be a promising class III drug for anti-arrhythmic therapy without the risk of proarrhythmia.